---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-421761"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-10-14T20:39:15+00:00"
generated_at: "2026-10-14T20:40:04.363887+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics adds Kristine Ball to board; Phase 3 relcobatinib trial to start before year-end

## Summary
- Board expanded from seven to eight directors; Ball appointed Class II director effective Oct. 14, 2026, term expiring at the 2028 annual meeting, and joins the Audit Committee.
- Compensation: $45,000/year as outside director plus $10,000/year for Audit Committee service, and stock options with grant-date fair value of about $650,000.
- Options vest 1/36th monthly, with full acceleration on a Change in Control; Ball also signed the company's standard indemnification agreement.
- Ball was CEO of Antiva Biosciences and Soteria Biotherapeutics and CFO of Menlo Therapeutics and Relypsa; she chairs Oruka Therapeutics' audit committee.
- Company reaffirmed plans to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) in previously treated CML before year-end 2026 after FDA alignment on ENABLE-2 design.

## SEC filing metadata
- accession: 0001193125-26-421761
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-10-14T20:39:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/0001193125-26-421761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/d13112d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-421761
- JSON: https://secwatch.observer/filing/0001193125-26-421761.json
- Plain text: https://secwatch.observer/filing/0001193125-26-421761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.